Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)	3 RUE MICHEL ANGE PARIS 75016
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)	101 RUE DE TOLBIAC PARIS 75013
HOSPICES CIVILS DE LYON	3 QUAI DES CELESTINS LYON CEDEX 2 69229
UNIVERSITE CLAUDE BERNARD LYON 1	43 BOULEVARD DU ONZE NOVEMBRE 1918 VILLEURBANNE 69100
CENTRE LEON BERARD	28 RUE LAËNNEC LYON 69008

International Classification(s)

• C12Q:MEASURING OR TESTING PROCESSES INVOLVING ENZYMES O....
• G01N:INVESTIGATING OR ANALYSING MATERIALS BY DETERMININ....

• [Classification Symbol]

• [Patents Count]

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Coste-Invernizzi, Isabelle	Chazey d'Azergues, FR	8	18
Kfoury, Alain	Lyons, FR	1	0
Lebecque, Serge	Civrieux d'Azergues, FR	9	33
Renno, Toufic	Civrieux d'Azergues, FR	9	18

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
7.5 Year Payment	$3600.00	$1800.00	$900.00	Dec 20, 2024
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Dec 20, 2028

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

DATE PUBLISHED	PUBLICATION/PATENT NO.	PUBLICATION TYPE
June 20, 2017	US,9683986,B2   US9683986B2	GRANTED PATENT AS SECOND PUBLICATION
November 06, 2014	US,20140329261,A1   US20140329261A1	FIRST PUBLISHED PATENT APPLICATION

Full Text

US Patent No: 9683986

Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interaction

---

 

Legal Events